ICU Medical (NASDAQ:ICUI) Upgraded by Wall Street Zen to Strong-Buy Rating

Wall Street Zen upgraded shares of ICU Medical (NASDAQ:ICUI) from a buy rating to a strong-buy rating in a research report sent to investors on Saturday morning.

A number of other equities research analysts have also recently weighed in on the stock. Weiss Ratings upgraded shares of ICU Medical from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, July 23rd. Raymond James Financial reiterated a “strong-buy” rating and issued a $200.00 target price on shares of ICU Medical in a report on Friday. Zacks Research lowered ICU Medical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 28th. KeyCorp raised their price target on ICU Medical from $164.00 to $182.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 21st. Finally, Sanford C. Bernstein cut ICU Medical to a “market perform” rating in a research note on Monday, June 15th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $192.80.

ICU Medical Stock Performance

Shares of ICU Medical stock opened at $184.56 on Friday. The firm has a market cap of $4.61 billion, a PE ratio of 156.41, a price-to-earnings-growth ratio of 2.58 and a beta of 0.74. The company has a quick ratio of 1.17, a current ratio of 2.34 and a debt-to-equity ratio of 0.60. ICU Medical has a 52 week low of $107.00 and a 52 week high of $192.85. The business’s fifty day simple moving average is $151.64 and its 200-day simple moving average is $141.02.

ICU Medical (NASDAQ:ICUI) last issued its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $2.37 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.91 by $0.46. The firm had revenue of $547.88 million during the quarter, compared to the consensus estimate of $533.44 million. ICU Medical had a return on equity of 7.94% and a net margin of 1.39%.The company’s quarterly revenue was up .5% on a year-over-year basis. During the same period last year, the company earned $2.10 EPS. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. Equities analysts forecast that ICU Medical will post 6.51 earnings per share for the current year.

Insider Activity at ICU Medical

In related news, Director David C. Greenberg sold 2,424 shares of ICU Medical stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $122.91, for a total value of $297,933.84. Following the completion of the transaction, the director owned 7,960 shares in the company, valued at approximately $978,363.60. The trade was a 23.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Virginia Ruth Sanzone sold 2,447 shares of the company’s stock in a transaction that occurred on Thursday, May 14th. The stock was sold at an average price of $124.08, for a total transaction of $303,623.76. Following the sale, the vice president directly owned 19,460 shares in the company, valued at approximately $2,414,596.80. The trade was a 11.17% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 2.10% of the company’s stock.

Institutional Trading of ICU Medical

A number of large investors have recently made changes to their positions in ICUI. Hilton Head Capital Partners LLC purchased a new position in ICU Medical in the fourth quarter worth approximately $32,000. Covestor Ltd raised its holdings in shares of ICU Medical by 22.1% in the 4th quarter. Covestor Ltd now owns 696 shares of the medical instruments supplier’s stock valued at $99,000 after purchasing an additional 126 shares in the last quarter. Strs Ohio raised its holdings in shares of ICU Medical by 60.0% in the 4th quarter. Strs Ohio now owns 800 shares of the medical instruments supplier’s stock valued at $114,000 after purchasing an additional 300 shares in the last quarter. Rockefeller Capital Management L.P. lifted its position in shares of ICU Medical by 21.6% during the 4th quarter. Rockefeller Capital Management L.P. now owns 823 shares of the medical instruments supplier’s stock worth $117,000 after purchasing an additional 146 shares during the last quarter. Finally, Kemnay Advisory Services Inc. purchased a new stake in shares of ICU Medical during the 4th quarter worth $120,000. 96.10% of the stock is currently owned by hedge funds and other institutional investors.

ICU Medical News Summary

Here are the key news stories impacting ICU Medical this week:

• Positive Sentiment: Quarterly earnings beat expectations: ICU Medical reported second-quarter adjusted EPS of $2.37, up from $2.10 a year earlier and well above the $1.91 analyst consensus. Revenue reached $547.9 million versus expectations of $533.4 million, with infusion systems cited as a key growth driver. ICU Medical Q2 results beat analyst expectations, driven by infusion systems
• Positive Sentiment: Higher 2026 earnings outlook: The company raised or updated fiscal 2026 EPS guidance to $8.60–$9.00, above the approximately $7.83 consensus estimate. This indicates management expects stronger profitability than Wall Street previously modeled. ICU Medical Announces Second Quarter 2026 Results and Updates its Fiscal Year 2026 Guidance
• Positive Sentiment: Analysts raised price targets: Piper Sandler increased its target from $163 to $195 and maintained an “overweight” rating. Needham raised its target from $165 to $187 and reiterated a “buy” rating. The revisions reinforce the view that the earnings beat and guidance update improve ICU Medical’s growth outlook. ICU Medical Analysts Boost Their Forecasts Following Upbeat Q2 Earnings
• Neutral Sentiment: Valuation remains demanding: Despite the favorable earnings news, ICU Medical trades at a high earnings multiple, meaning further gains may depend on the company delivering against its elevated guidance and sustaining growth.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.